In the Claims:

Please amend claim 6 to read as follows:

B1

6. (Amended) A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with a binding agent that binds to a polypeptide comprising at least 10 contiguous amino acid residues of a polypeptide encoded by the polynucleotide sequence of SEQ ID NO:808;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

Please add new claims 18–23 to read as follows:

B2

18. (New) A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

(b) contacting the biological sample with a binding agent that binds to a polypeptide comprising an amino acid sequence having at least 75% identity to the amino acid sequence of a polypeptide encoded by the polynucleotide sequence of SEQ ID NO:808;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

19. (New) A method for detecting the presence of a cancer in a patient, comprising the steps of:

(a) obtaining a biological sample from the patient;

B2 cncld

(b) contacting the biological sample with a binding agent that binds to a polypeptide comprising an amino acid sequence having at least 75% identity to at least 20 contiguous residues of an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:808;

(c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.

20. (New) The method of claim 6, wherein the binding agent is an antibody or antigen-binding fragment thereof.

21. (New) The method of claim 20, wherein the antibody is a monoclonal or polyclonal antibody.

22. (New) The method of claim 6, wherein the cancer is lung cancer.

23. (New) The method of claim 6, wherein the biological sample is selected from the group consisting of: lung tissue, blood, sera, sputum, urine, and a tumor biopsy.

REMARKS

In response to the Restriction Requirement dated July 2, 2002, claim 6 has been elected. Claims 18–23 were added to more clearly describe specific aspects of the elected invention. It is urged that support for the amendments may be found throughout the specification as originally filed, and, therefore, the amendments do not constitute new matter. Specific support for newly added claims 18 and 19 may be found, for example, on page 148, lines 22-28. Support for fragments of polypeptides encoded by SEQ ID NO:808 is provided, for example, on page 116, lines 1-9, and support for polypeptides with at least 75% identity to polypeptides encoded by SEQ ID NO:808 is provided, for example, on page 117, lines 15-18. In addition, support for monoclonal and polyclonal antibodies and antigen-binding fragments thereof is provided, for